Voluntary nationwide recall: Atovaquone (Bionpharma – September)

Oct. 2024Pharmacy Updates

Bionpharma Inc. is recalling one lot, lot 2310083, of Atovaquone Oral Suspension, 750 mg/mL. Atovaquone is used to prevent a fungal infection called pneumocystis jirovecii pneumonia in adults and adolescents age 13 and older.

This drug is being recalled because Cohnella bacteria was found in the product. Using this contaminated drug can cause life-threatening swelling of the heart and permanent damage to the body’s soft tissue.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Atovaquone, you should stop using the product and return it to the place of purchase.

As of Sept. 17, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Bionpharma at 1-888-235-2466. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

The importance of PRD forms for complex patients and staying updated on changes

Personal representative designation (PRD) forms are critical to the care process for patients and providers alike. Not only do PRDs support accurate, efficient, and compliant patient care—they also streamline administrative processes.
Aug. 2025Important Notices

Important announcement: UPMC Health Plan retires MP.PA.147

This communication is in regards to UPMC Health Plan Policy MP.PA.147 – Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older. UPMC Health Plan previously communicated that the prior authorization requirement under this policy would be paused until Sept. 1, 2025. However, policy MP.PA.147 has been retired, and this policy will no longer be implemented or active.
Aug. 2025Important Notices

CMS expands Medicare Advantage RADV audits to all eligible plans

On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a substantial expansion of its Risk Adjustment Data Validation (RADV) audit program for Medicare Advantage plans.
Aug. 2025What's New